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Human immunodeficiency virus infection and child sexual 
abuse 
Hendrik Simon Schaaf 
Child sexual abuse (CSA) has not previously been regarded as 
important in the overall transmission of HIV infection to 
childrenY However, with both CSA'·' and HIV infection on the 
increase, the risk of acquiring HIV infection through CSA is 
real, and several reports of such transmission have been 
documented.'·' The incidence in children of HIV acquired by 
CSA is unknown, but the prevalence in Africa among sexually 
abused children, mainly with penetrative injuries, ranges from 
1% (2/200 children) in Cape Town, South Africa, to as high as 
33.8% (24/71 children) in Cameroon.'·' The author has 
experience of at least 10 children who became HIV-infected 
almost certainly through sexual abuse over the past 10 years. 
Risk of HIV transmission by sexual 
abuse 
The risk of transmission during sexual abuse depends on 
factors such as the HIV status of the perpetrator (mostly 
unknown by the investigating team) and the child (although an 
already infected child may be reinfected), the extent of 
penetration and mucosal injury that occurs in the penetrated 
orifice (vaginal, anal or oral), the presence of other sexually 
transmitted infections (STis), whether the perpetrator 
ejaculated during the incident(s), and the number of exposures 
to abuse. 
In adult women, the risk of transmission from one episode of 
vaginal-penile contact is 0.1 - 0.2%, while the risk for 
transmission during adult penile-anal contact is estimated at 
0.1 - 3.0%.8 The risk of oral-genital contact is not known. In the 
case of CSA the risk of transmission of HIV during a single 
episode of abuse is unknown," but because of greater risk of 
mucosal trauma, the risk is likely to be higher than in 
consensual adult sexual contact. 
In a survey of children attending the Family Clinic for HIV 
at Tygerberg Academic Hospital between 1997 and 2001,5 of 
274 children (1.8%) were infected through CSA (M F Cotton-
personal communication). Between 20% and 30% of infants 
born to HIV-infected mothers become infected in the absence of 
intervention. Should these children be victims of CSA it will be 
difficult to establish whether HIV infection was vertically 
transmitted or acquired by CSA if they had not been tested 
previously. Molecular investigations such as phylogenetic 
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analyses have been used in some cases of suspected 
transmission by CSA or other forms of unlikely transmission, 
but this is expensive, not freely available, and difficult to 
interpret because of rapid and continuous changes in the 
virus.'·'" 
Screening for HIV in sexually abused 
children 
HIV counselling should be an integral part of the assessment of 
all children who have suffered sexual abuse, if not for 
screening, then at least to allay fears about HIV infection. In 
itself CSA causes physical and/ or psychological trauma and 
children are often stigmatised. A possible further diagnosis of 
HIV infection, whether sexually or otherwise acquired, will 
certainly add to the trauma and stigmatisation experienced by 
the individual and the family. Caregivers or young people will 
have questions regarding HIV after CSA, and these should be 
carefully considered and dealt with sensitively and without 
delay. All staff working with children who have suffered CSA 
should therefore have a basic knowledge about HIV infection, 
HIV post-exposure prophylaxis (PEP) and HIV care resources. 
In sub-Saharan Africa, where the prevalence of HIV infection 
is high, the need for testing will generally be greater than in 
countries with a lower HIV prevalence. A careful history may 
reveal potential risk factors regarding the abuse and the abuser 
which might make testing more pertinent! 
Screening policies for HIV testing among sexually abused 
children have varied from recommendations for selective 
testing to recommendations for universal testing.' Selective 
recommendations seem to be more widely accepted. 
Table I summarises the circumstances in which HIV 
serological testing in CSA have been recommended.'· 2•6 
HIV testing and informed consent 
All parents/guardians of children under the age of 14 years, 
and adolescents above 14 years of age with or without their 
parents' consent, presenting to a health facility after being 
sexually abused should be counselled by the examining health 
worker about the potential risk of HIV transmission. If the 
child presents within 72 hours of being sexually abused, 
antiretroviral drugs should be offered to prevent HIV 
transmission. 
The following points should be covered in the counselling: 
1. The risk of transmission through CSA is not known (see 
above). 
2. There is strong evidence to support the use of PEP in 
preventing HIV transmission in occupational exposure."-'' 
Although the effectiveness of PEP in non-occupational 
exposure such as sexual abuse cases is not known, it is now 
widely accepted on the basis of successes with occupational 
PEP."-14•15 However, HIV PEP is not a cure for HIV infection. 
3. Acceptance of HIV PEP is voluntary. Acceptance of HIV 
PEP requires the patient and/or caregiver to commit to 
completing a 28-day regimen and a follow-up programme. The 
importance of compliance should be emphasised. 
4. The common adverse events of the drugs used should be 
explained. Most adverse events are manageable, but rarely 
these may be severe. Decisions to provide HIV PEP must 
balance the potential benefits and risks.14•16 The adverse events 
of antiretroviral drugs may be aggravated when taken with 
other medication such as antituberculosis agents. 
5. If parents/guardians request antiretroviral prophylaxis 
more than 72 hours after sexual abuse, it should be explained 
that this will have no impact on preventing HIV transmission. 
Screening for CSA in HIV-infected 
children 
Health care workers should consider CSA as a possible reason 
for acquisition of HIV infection especially in older children 
diagnosed with HIV or in those whose mothers are HIV-
negative.'-17 In our experience most children do not readily 
disclose that they have been sexually abused for a variety of 
reasons. Several of our children have been identified as having 
been sexually abused only after presenting with HIV infection 
and its related complications. Others were seen as acute CSA 
cases and initial HIV serological testing was done and found to 
be negative, but no follow-up was arranged and they returned 
years later with clinically evident HIV infection with no other 
subsequent risk factors for transmission. 
Testing of the perpetrator of CSA 
Testing the alleged perpetrator is fraught with legal and ethical 
issues regarding the rights and confidentiality of the 
individual. Currently it seems that the HIV status of the 
alleged perpetrator of CSA can only be tested if s/he is willing 
to be tested, even if under arrest. The police cannot order a 
health care worker to perform an HIV test unless the arrested 
person consents. If the HIV status of the alleged perpetrator is 
known to a doctor, the latter should be informed of the 
situation and s/hemay then ask the alleged perpetrator if this 
information could be disclosed to the person managing the 
child victim. If the perpetrator refuses, confidentiality can be 
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breached. The doctor should, however, first inform the 
perpetrator that confidentiality is going to be breached in the 
best interests of the child victim's health. 
Prevention of HIV infection through 
CSA 
HIV post-exposure prophylaxis regimens 
Zidovudine (AZT) and lamivudine (3TC) are currently 
included in most HIV PEP regimens because of their 
demonstrated reduction in HIV transmission in occupational 
exposures and because they are generally well tolerated by 
patients."·" With the roll-out of antiretroviral therapy in South 
Africa, possible development of drug resistance should be 
taken into account as in other countries, and some authors 
advise substituting other nucleotide reverse transcriptase 
inhibitors (NRTls) for AZT and 3TC if it is known that the 
source case has been taking these agents.'9 
Twice-daily regimens should be used where possible, and 
HIV PEP should be administered as soon as possible (within 
hours) after the abuse. Health care workers should not wait for 
HIV test results before starting PEP if there is an indication for 
its use. If the child is already known to be HIV-infected PEP 
should not be given, but the child should be referred to an 
appropriate HIV clinic for further management. If the initial 
HIV test is positive, or by further evaluation of the case it 
becomes clear that PEP is not indicated, prophylaxis can be 
discontinued. Prophylaxis is also not indicated if the child 
presents more than 72 hours after the incident. 
Although some authors recommend a two-drug regimen 
(AZT plus 3TC) as HIV PEP in some circumstances, most 
guidelines recommend a three-drug regimen (two NRTis plus a 
protease inhibitor)."·''·'' Protease inhibitors are the main item of 
controversy in HIV PEP regimens because they are more 
expensive, have more unpleasant adverse events, and their 
benefit in PEP has not yet been established." Drugs and doses 
are summarised in Table II. 
Children and adolescents started on HIV PEP should receive 
sufficient medication for .3 - 7 days and be seen for follow-up 
within this period to assess adherence and tolerance of the 
regimen. If the regimen is tolerated and they are adherent to 
therapy; the rest of the 28-day PEP course should be supplied. 
Follow-up HIV testing 
Er-n All sexually abused children should be followed up in a health a:u 
care setting where appropriate medical and counselling 
resources are available. In those who are at risk for HIV 
transmission serological testing should be performed at 4 - 6 
weeks, and at 3 and 6 months after exposure. In our experience 
both compliance with prophylaxis regimens and follow-up 
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remain major problems in the effective management of these 
children. 
Prevention of CSA 
A clear message should be proclaimed by all political and 
community leaders that CSA is unacceptable and inexcusable. 
More effective medical examinations, police and social work 
investigations and successful prosecutions with the appropriate 
punishments could deter many male perpetrators from CSA.20 
Myths regarding the cure of STDs and particularly HIV by 
having sex with a virgin, a mistaken belief still held by many, 
must be opposed vigorously.'1•22 More complex, but no less 
important in curbing CSA, are issues of gender inequality with 
women and children being the victims, extreme levels of 
poverty, and disruption of families. 
Disclosure of diagnosis to an HIV-
infected child 
There is an understandable fear among parents of disclosing 
the HIV status to their children in the case of vertically 
transmitted HIV, as the disease is still very much stigmatised 
and parents fear that children will reveal their status to their 
friends and in this way to the community.23 According to 
reports mainly from Western countries, the majority of parents 
reveal the status to their children from about 8 -10 years of 
age.24 
Children infected with HIV through CSA are generally older 
and mothers are mainly HIV-negative.' Disclosure to these 
children could be as difficult even though this might not be a 
family disease. No reports on disclosure to sexually abused 
children could be identified. 
Honesty probably remains the most important component of 
disclosure together with a well-established support system to 
which the family and/ or child could turn. Neither parents nor 
health workers want inadvertently to inflict more suffering on 
a child than is already present from the abuse and illness 
itself.'' However, according to the American Academy of 
Pediatrics there does not appear to be evidence to support the 
fear that disclosure of HIV infection to children will cause 
negative consequences." Disclosure may be advantageous in 
that it allows for better understanding of the illness, more open 
involvement in medical care decisions, increased opportunities 
for support and improved trust in the health care providers.27•28 
Children often suspect their HIV status long before 
disclosure.'' However, disclosure remains a difficult task, best 
managed by parents together with a paediatric HIV 
interdisciplinary team, involving at least medical staff, social 
workers, psychologists and psychiatrists, and trained 
counsellors. Gerson et al. 25 describe in detail the successful 
process of disclosure used at their institution using the 
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Table I. Summary of circumstances in which HIV testing is 
recommended'·'·' 
Recommendations for HIV serological testing in child sexual 
abuse cases 
1. The child has another acquired sexually transmitted disease 
2. The child has an anal or a vaginal injury or discharge or 
other mucosal injury suggestive of abuse 
3. The child has been documented to have experienced penile 
invasive abuse 
4. The child is reported for suspected CSA and outcome is 
confirmed, suspected or unknown 
5. The child is exposed to a known HIV-infected perpetrator of 
abuse or a perpetrator with unknown HIV status, especially 
if risk factors are identified, such as clinical findings of HIV 
infection, previously having served a prison sentence, 
intravenous drug user and multiple sexual partners 
6. The child was abused by multiple assailants 
7. The child has clinical findings compatible with HIV infection 
8. Frequent exposure to abuse 
9. A history of high-risk behaviour in an adolescent 
10. Parent or young person requesting testing 
Table II. HIV post-exposure prophylaxis regimen for sexually 
abused children 
Age group and 28-day antiretroviral regimen-. drug 
and dose 
~ 13 years of age(~ 35- 40 kg) 
*Zidovudine/lamivudine combination (Combivir) 
1 tablet twice daily 
plus (risk and availability dependent) 
'Lopinavir/ritonavir (Kaletra) > 12 years or> 40 kg: 5 ml or 
3 capsules twice daily 
< 13 years of age 
*Zidovudine 180 mg/m2 body surface area/ dose orally twice 
daily (maximum 300 mg/ dose) 
plus 
*Lamivudine 4 mg/kg/ dose orally twice daily (maximum 
150 mg/ dose) 
plus (risk and availability dependent) 
'Lopinavir /ritonavir (Kaletra) 
6 months - 12 years: 7- 15 kg: 12 mg/kg twice daily 
Up to 12 years: 15- 40 kg: 10 mg/kg twice daily 
> 12 years or > 40 kg: 5 ml or 3 capsules twice daily 
* Possible alternative nucleoside reverse transcriptase inhibitors (NRT!s) 
Abacavir (Ziagen) 8 mg/kg/dose orally twice daily (maximum 
300 mg/ dose) 
Didanosine (ddl/Videx) 90-150 mg/rrt'/dose orally twice daily (maximum 
200 mg/ dose) 
Stavudine (d4T /Zerit) 1 mg/kg/dose orally twice daily (maximum 30 mg 
from 30 - 60 kg) 
'Possible alternative protease inhibitors 
Nelvinavir (Viracept) 1 250 mg (5 x 250 mg tablets) twice daily 
following framework: (i) information gathering and trust 
building; (ii) education; (iii) determining when the time is right 
for disclosure; (iv) the actual disclosure event; and (v) 
monitoring post-disclosure coping and managing disclosure-
related problems or challenges. 
The final decision when to disclose remains with the parent 
-- __________________ ....;_ ______________ ..... __________________ _ 
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or caregiver, but they mostly need help. The sharing of difficult 
news with children is complicated, but health care providers 
should take on this responsibility and be prepared. 
Disclosing of their HIV status to their friends or peers is 
another aspect of disclosure in which children need guidance. 
They should be warned not to be indiscriminate in telling peers 
that they have HIV. Although some reports show a positive 
clinical effect with disclosure to trusted friends, such as a rise 
in CD4 count, others warn that disclosure often has a negative 
psychological impact.""' 
Long-term consequences of CSA 
Many studies have shown that CSA in both girls and boys is 
linked to health problems in adolescence and adulthood, 
including risky sexual behaviour, more sexually transmitted 
diseases, and injection drug use.31' 33 Currently, the focus is 
usually on the individual child's sexual abuse, but future 
treatment should also aim much more at addressing family 
function and the child's feelings of despair. 
Conclusion 
The role of CSA as a cause of HIV infection in children is 
underestimated and needs further research, especially in 
countries with high HIV prevalence. All possible means should 
be used to prevent CSA in our communities. However, when 
prevention fails and children become victims of this crime, the 
least we can do is to try and prevent the serious consequences 
such as HIV infection with all the means we have available. 
Thanks to Dr Mark F Cotton, Director, KID-CRU (Children's 
Infectious Diseases Clinical Research Unit), and Department of 
Paediatrics and Child Health, Faculty of Health Sciences, 
Stellenbosch University, for reviewing the manuscript. 
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